Marex Group plc [MRX] vs Morgan Stanley [MS] Detailed Stock Comparison
Marex Group plc
NASDAQ
Loading...
Morgan Stanley
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Marex Group plc wins in 6 metrics, Morgan Stanley wins in 11 metrics, with 0 ties. Morgan Stanley appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Marex Group plc | Morgan Stanley | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 10.57 | 16.40 | Marex Group plc |
| Price-to-Book Ratio | 2.48 | 2.35 | Morgan Stanley |
| Debt-to-Equity Ratio | 887.54 | 438.54 | Morgan Stanley |
| PEG Ratio | 11.74 | 1.01 | Morgan Stanley |
| EV/EBITDA | 1.94 | N/A | N/A |
| Profit Margin (TTM) | 10.14% | 22.49% | Morgan Stanley |
| Operating Margin (TTM) | 14.55% | 34.12% | Morgan Stanley |
| EBITDA Margin (TTM) | 14.55% | 34.12% | Morgan Stanley |
| Return on Equity | 26.52% | 14.13% | Marex Group plc |
| Return on Assets (TTM) | 1.09% | 1.16% | Morgan Stanley |
| Free Cash Flow (TTM) | $1.14B | $-2.10B | Marex Group plc |
| Dividend Yield | 2.01% | 2.15% | Morgan Stanley |
| 1-Year Return | 48.60% | 45.27% | Marex Group plc |
| Price-to-Sales Ratio (TTM) | 0.98 | 3.52 | Marex Group plc |
| Enterprise Value | $1.68B | $158.15B | Morgan Stanley |
| EV/Revenue Ratio | 0.64 | 2.41 | Marex Group plc |
| Gross Profit Margin (TTM) | 38.83% | N/A | N/A |
| Revenue per Share (TTM) | $37 | $41 | Morgan Stanley |
| Earnings per Share (Diluted) | $3.31 | $8.83 | Morgan Stanley |
| Beta (Stock Volatility) | N/A | 1.32 | N/A |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Marex Group plc vs Morgan Stanley Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Marex Group plc | -0.22% | 2.94% | -5.36% | -17.71% | -0.61% | 10.76% |
| Morgan Stanley | 2.76% | 2.34% | 5.70% | 17.23% | 13.89% | 18.62% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Marex Group plc | 48.60% | 89.58% | 89.58% | 89.58% | 89.58% | 89.58% |
| Morgan Stanley | 45.27% | 70.51% | 179.86% | 334.71% | 491.37% | 187.08% |
Performance & Financial Health Analysis: Marex Group plc vs Morgan Stanley
| Metric | MRX | MS |
|---|---|---|
| Market Information | ||
| Market Cap | $2.55B | $231.12B |
| Market Cap Category | Mid cap | Mega cap |
| 10 Day Avg. Volume | 1,212,790 | 4,617,060 |
| 90 Day Avg. Volume | 1,201,233 | 5,290,947 |
| Last Close | $36.02 | $148.02 |
| 52 Week Range | $22.33 - $49.34 | $94.09 - $149.08 |
| % from 52W High | -27.00% | -0.71% |
| All-Time High | $49.34 (May 12, 2025) | $148.90 (Aug 22, 2025) |
| % from All-Time High | -27.00% | -0.59% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.13% | 0.11% |
| Quarterly Earnings Growth | 0.29% | 0.15% |
| Financial Health | ||
| Profit Margin (TTM) | 0.10% | 0.22% |
| Operating Margin (TTM) | 0.15% | 0.34% |
| Return on Equity (TTM) | 0.27% | 0.14% |
| Debt to Equity (MRQ) | 887.54 | 438.54 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $14.14 | $61.59 |
| Cash per Share (MRQ) | $148.95 | $352.68 |
| Operating Cash Flow (TTM) | $1.64B | $-17,670,000,640 |
| Levered Free Cash Flow (TTM) | $204.70M | $12.80B |
| Dividends | ||
| Last 12-Month Dividend Yield | 2.01% | 2.15% |
| Last 12-Month Dividend | $0.72 | $2.79 |
Valuation & Enterprise Metrics Analysis: Marex Group plc vs Morgan Stanley
| Metric | MRX | MS |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 10.57 | 16.40 |
| Forward P/E | 11.74 | 18.26 |
| PEG Ratio | 11.74 | 1.01 |
| Price to Sales (TTM) | 0.98 | 3.52 |
| Price to Book (MRQ) | 2.48 | 2.35 |
| Market Capitalization | ||
| Market Capitalization | $2.55B | $231.12B |
| Enterprise Value | $1.68B | $158.15B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 0.64 | 2.41 |
| Enterprise to EBITDA | 1.94 | N/A |
| Risk & Other Metrics | ||
| Beta | N/A | 1.32 |
| Book Value per Share (MRQ) | $14.14 | $61.59 |
Financial Statements Comparison: Marex Group plc vs Morgan Stanley
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | MRX | MS |
|---|---|---|
| Revenue/Sales | $865.70M | $16.52B |
| Cost of Goods Sold | $544.70M | N/A |
| Gross Profit | $321.00M | N/A |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | $239.30M | N/A |
| EBITDA | $247.90M | N/A |
| Pre-Tax Income | $98.00M | $5.54B |
| Income Tax | $25.50M | $1.17B |
| Net Income (Profit) | $72.50M | $4.37B |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | MRX | MS |
|---|---|---|
| Cash & Equivalents | $2.61B | $60.84B |
| Total Current Assets | $23.78B | N/A |
| Total Current Liabilities | $21.77B | N/A |
| Long-Term Debt | $1.54B | $303.93B |
| Total Shareholders Equity | $1.05B | $107.85B |
| Retained Earnings | $775.30M | $107.65B |
| Property, Plant & Equipment | $86.80M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | MRX | MS |
|---|---|---|
| Operating Cash Flow | N/A | $-67.29B |
| Capital Expenditures | N/A | $-713.00M |
| Free Cash Flow | N/A | $-24.69B |
| Debt Repayment | N/A | $-20.85B |
| Common Stock Repurchase | N/A | $-2.03B |
Short Interest & Institutional Ownership Analysis
| Metric | MRX | MS |
|---|---|---|
| Shares Short | 3.16M | 14.60M |
| Short Ratio | 2.45 | 2.55 |
| Short % of Float | 0.09% | 0.01% |
| Average Daily Volume (10 Day) | 1,212,790 | 4,617,060 |
| Average Daily Volume (90 Day) | 1,201,233 | 5,290,947 |
| Shares Outstanding | 70.29M | 1.61B |
| Float Shares | 51.28M | 1.21B |
| % Held by Insiders | 0.25% | 0.24% |
| % Held by Institutions | 0.76% | 0.63% |
Dividend Analysis & Yield Comparison: Marex Group plc vs Morgan Stanley
| Metric | MRX | MS |
|---|---|---|
| Last 12-Month Dividend | $0.72 | $2.79 |
| Last 12-Month Dividend Yield | 2.01% | 2.15% |
| 3-Year Avg Annual Dividend | $0.24 | $3.10 |
| 3-Year Avg Dividend Yield | 0.45% | 0.90% |
| 3-Year Total Dividends | $0.72 | $9.31 |
| Ex-Dividend Date | Aug 26, 2025 | Jan 31, 2025 |